Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Thermo Fisher Scientific and Nuclea Biotechnologies announce diabetes alliance

Thermo Fisher Scientific and Nuclea Biotechnologies announce diabetes alliance

5th June 2014

Thermo Fisher Scientific has announced a new collaboration with Nuclea Biotechnologies to accelerate the translation of multiplexed methods to quantify type 2 diabetes markers.

The companies aim to develop novel multiplexed research methods for high-throughput quantification of native insulin and its therapeutic analogues. Monitoring levels of such markers may be useful in predicting the response to therapy for this form of diabetes.

Researchers on the project will benefit from Nuclea's extensive experience in developing and commercialising biomarkers and clinical tests, with work to be based at Thermo Fisher's Biomarker Research Initiatives in Mass Spectrometry (BRIMS) Center.

Scientists from Nuclea and the BRIMS Center will develop multiplexed mass spectrometry (MS)-based research methods, which Nuclea will use to analyse donor plasma samples from Boston-based diabetes research collaboration.

Mary Lopez, director of the BRIMS Center at Thermo Fisher Scientific, said: "The real-world application of multiplexed MS-based methods to type 2 diabetes presents an opportunity to advance research in this crucial area."

Earlier this year, the firm announced a new agreement with IntegenX, giving it the right to distribute Life Technologies' GlobalFiler Express chemistry on its RapidHIT platform.ADNFCR-8000103-ID-801726178-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.